🇺🇸 FDA

Company profile · Sponsor

Arbutus

Arbutus Biopharma Corp

ABUS · NYSE biotech WARMINSTER, PA, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Arbutus (ABUS) is a biotech company. headquartered in WARMINSTER, PA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ABUS
Exchange NYSE
Company type biotech
Headquarters WARMINSTER, PA, USA
SEC CIK 0001447028

Pipeline (13)

Search pipeline →

  1. AB-729

    Arbutus

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  2. ARB-001467

    Arbutus

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  3. Imdusiran

    Arbutus

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  4. Imdusiran (AB-729)

    Arbutus

    Chronic Hepatitis B

    phase 2 small molecule active

    1 trial

  5. Imdusiran, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Arbutus

    Chronic HBV Infection

    phase 2 small molecule active

    1 trial

  6. TKM-080301

    Arbutus

    Cancer

    phase 2 small molecule completed

    1 trial

  7. TKM-080301

    Arbutus

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  8. AB-101

    Arbutus

    Chronic Hepatitis b

    phase 1 small molecule completed

    1 trial

  9. AB-836

    Arbutus

    Chronic Hepatitis

    phase 1 small molecule terminated

    1 trial

  10. PRO-040201

    Arbutus

    Hypercholesterolemia

    phase 1 small molecule terminated

    1 trial

  11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  12. TKM-100201

    Arbutus

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial

  13. TKM-100802 for Injection

    Arbutus

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial

Patents (8)

Search patents →

  1. US 12357705

    Negatively charged peg-lipid conjugates

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12350383

    Cationic lipids containing silicon

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12251470

    Lipid nanoparticle formulations

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12129467

    Non-liposomal systems for nucleic acid delivery

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12083118

    Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12043833

    Targeted compositions

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12042541

    Lipids and compositions for the delivery of therapeutics

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12023383

    Lipid compositions

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Arbutus?

Arbutus (ABUS) is a biotech company. headquartered in WARMINSTER, PA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Arbutus sponsor?

We track 13 ClinicalTrials.gov-linked programs for Arbutus, including AB-729 and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Arbutus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.